智通财经APP讯,英派药业-B(07630)发布公告,根据上海证券交易所及深圳证券交易所分别发出的公告,公司H股已获纳入沪港通及深港通合资格证券名单,自2026年9月7日起生效。
公司H股获纳入沪港通及深港通合资格证券名单后,中国内地合资格投资者将可透过上海证券交易所及深圳证券交易所直接投资公司H股。公司认为,获纳入沪港通及深港通将有利于进一步扩大公司的投资者基础,并有望提升公司H股的交易流动性。
智通财经APP讯,英派药业-B(07630)发布公告,根据上海证券交易所及深圳证券交易所分别发出的公告,公司H股已获纳入沪港通及深港通合资格证券名单,自2026年9月7日起生效。
公司H股获纳入沪港通及深港通合资格证券名单后,中国内地合资格投资者将可透过上海证券交易所及深圳证券交易所直接投资公司H股。公司认为,获纳入沪港通及深港通将有利于进一步扩大公司的投资者基础,并有望提升公司H股的交易流动性。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.